Less than $1000 to save a life from cryptococcal meningitis with flucytosine
December 20 2019
Data from the ACTA trial suggests that 14 days of dual therapy (fluconazole+flucytosine) reduces mortality from 54% to 35% in the first 10 weeks. The cost of treating all patients worldwide would be around $40,604,200 per year - equivalent to only $973 per life saved.
Update of the EORTC Consensus Definitions of Invasive Fungal Disease
December 09 2019
The EORTC consensus definitions of invasive fungal infections have now been updated to include new patient groups (e.g. children and those taking ibrutinib) and diseases (e.g. Pneumocystis, endemic mycoses), and to reflect recent progress in diagnostics including Aspergillus/Candida PCR and galactomannan
Diagnosis of tinea capitis in adults is challenging
December 09 2019
Tinea capitis is uncommon in adults, and often initially misdiagnosed as bacterial folliculitis, allergic contact dermatitis, psoriasis or eczema
NICU fluconazole prophylaxis may lead to Malassezia colonisation and fungaemia
October 17 2019
IDSA recommends fluconazole prophylaxis for the first six weeks in premature neonates weighing <1kg in units with high rates (>10%) of invasive candidiasis. Dr Chen and colleagues in Taiwan found that introducing fluconazole prophylaxis reduced cases of candidaemia from 1-2 cases per year (per ~780 patients) to zero. However, Malassezia colonisation and fungaemia rose during this time.
Fungal infection burdens presented at TIMM: Morocco, Sudan, Cote d’Ivoire, Tajikistan, Azerbaijan
October 14 2019
Estimates of the incidence and prevalence of fungal infections were presented this week at TIMM2019 (Nice, France) for a further 5 countries: Morocco, Sudan, Cote d’Ivoire, Tajikistan and Azerbaijan.